INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
Home/Topics/Companies & Institutions/Daiichi Sankyo
Back to Newsroom
🏢Organization Dossier

Daiichi Sankyo

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

1 Stories Indexed
Last Updated: Just Now
Verified Entity Intelligence
Global Health & Biotech 06 Oct 2026, 08:29 AM IST

AstraZeneca CEO Says Summit Drug Could Anchor Next Wave of Cancer Combinations After $2 Billion Bet

AstraZeneca Chief Executive Pascal Soriot said Summit Therapeutics’ cancer drug could become a foundation for the next generation of combination therapies, underscoring why the Anglo-Swedish drugmaker has committed about $2 billion to the biotech. The comments come as AstraZeneca and Daiichi Sankyo move to test Summit’s ivonescimab alongside Datroway, a sign that large pharmaceutical groups are racing to secure the most promising assets in oncology.

By RDU Global Wire5 min read

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Daiichi Sankyo: